V
Valentine Comaills
Researcher at Harvard University
Publications - 25
Citations - 2206
Valentine Comaills is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Circulating tumor cell. The author has an hindex of 13, co-authored 21 publications receiving 1657 citations. Previous affiliations of Valentine Comaills include Spanish National Research Council & Pablo de Olavide University.
Papers
More filters
Journal ArticleDOI
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Min Yu,Min Yu,Aditya Bardia,Nicola Aceto,Francesca Bersani,Marissa W. Madden,Maria C. Donaldson,Rushil Desai,Huili Zhu,Valentine Comaills,Zongli Zheng,Zongli Zheng,Ben S. Wittner,Petar Stojanov,Elena F. Brachtel,Dennis C. Sgroi,Ravi Kapur,Toshihiro Shioda,David T. Ting,Sridhar Ramaswamy,Gad Getz,Gad Getz,A. John Iafrate,Cyril H. Benes,Mehmet Toner,Shyamala Maheswaran,Daniel A. Haber,Daniel A. Haber +27 more
TL;DR: It has been proposed that the isolation, ex vivo culture, and characterization of CTCs may provide an opportunity to noninvasively monitor the changing patterns of drug susceptibility in individual patients as their tumors acquire new mutations.
Journal ArticleDOI
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Stephanie A. Yazinski,Valentine Comaills,Rémi Buisson,Marie-Michelle Genois,Hai Dang Nguyen,Chu Kwen Ho,Tanya Todorova Kwan,Tanya Todorova Kwan,Robert Morris,Sam Lauffer,André Nussenzweig,Sridhar Ramaswamy,Cyril H. Benes,Daniel A. Haber,Daniel A. Haber,Shyamala Maheswaran,Michael J. Birrer,Lee Zou +17 more
TL;DR: ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCa1-deficient cells, overcoming both resistance mechanisms.
Journal ArticleDOI
Sox2 promotes tamoxifen resistance in breast cancer cells
Marco Piva,Giacomo Domenici,Oihana Iriondo,Miriam Rábano,Bruno M Simões,Valentine Comaills,Inmaculada Barredo,Jose A. López-Ruiz,Ignacio Zabalza,Robert M. Kypta,Maria dM Vivanco +10 more
TL;DR: Examination of patient tumours indicated that Sox2 levels are higher in patients after endocrine therapy failure, and also in the primary tumours of these patients, compared to those of responders, suggesting that development of tamoxifen resistance is driven by Sox2‐dependent activation of Wnt signalling in cancer stem/progenitor cells.
Journal ArticleDOI
Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis
Richard Y. Ebright,Sooncheol Lee,Ben S. Wittner,Kira L. Niederhoffer,Benjamin Nicholson,Aditya Bardia,Samuel S. Truesdell,Devon F. Wiley,Benjamin Wesley,Selena S. Li,Andy Mai,Nicola Aceto,Nicole Vincent-Jordan,Annamaria Szabolcs,Brian Chirn,Johannes Kreuzer,Valentine Comaills,Mark Kalinich,Wilhelm Haas,David T. Ting,Mehmet Toner,Mehmet Toner,Shobha Vasudevan,Daniel A. Haber,Daniel A. Haber,Shyamala Maheswaran,Douglas S. Micalizzi +26 more
TL;DR: An in vivo genome-wide CRISPR activation screen in CTCs from breast cancer patients was conducted to identify genes that promote distant metastasis in mice and found that cells with increased expression levels of certain ribosomal proteins and regulators of translation had greater metastatic capacity in a mouse model.
Journal ArticleDOI
Effects of estrogen on the proportion of stem cells in the breast.
Bruno M Simões,Marco Piva,Oihana Iriondo,Valentine Comaills,Jose A. López-Ruiz,Iñaki Zabalza,Jon A. Mieza,Olga Acinas,Maria dM Vivanco +8 more
TL;DR: It is shown that estrogen reduces the proportion of stem cells in the normal human mammary gland and in breast cancer cells, and may provide an explanation for the better prognosis of ER-positive tumors.